...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Novel macrocyclic HCV NS3 protease inhibitors derived from alpha-amino cyclic boronates.
【24h】

Novel macrocyclic HCV NS3 protease inhibitors derived from alpha-amino cyclic boronates.

机译:衍生自α-氨基环状硼酸盐的新型大环HCV NS3蛋白酶抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

A novel series of P2-P4 macrocyclic HCV NS3/4A protease inhibitors with alpha-amino cyclic boronates as warheads at the P1 site was designed and synthesized. When compared to their linear analogs, these macrocyclic inhibitors exhibited a remarkable improvement in cell-based replicon activities, with compounds 9a and 9e reaching sub-micromolar potency in replicon assay. The SAR around alpha-amino cyclic boronates clearly established the influence of ring size, chirality and of the substitution pattern. Furthermore, X-ray structure of the co-crystal of inhibitor 9a and NS3 protease revealed that Ser-139 in the enzyme active site traps boron in the warhead region of 9a, thus establishing its mode of action.
机译:设计并合成了一系列新型的P2-P4大环HCV NS3 / 4A蛋白酶抑制剂,其在P1位点具有α-氨基环硼酸酯作为战斗部。当与它们的线性类似物相比时,这些大环抑制剂在基于细胞的复制子活性方面显示出显着的改善,化合物9a和9e在复制子测定中达到了亚微摩尔的效价。围绕α-氨基环状硼酸盐的SAR清楚地确定了环大小,手性和取代模式的影响。此外,抑制剂9a和NS3蛋白酶的共晶体的X射线结构表明,酶活性位点中的Ser-139在9a的战斗部区域捕获了硼,从而确立了其作用方式。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号